Variable chimerism, graft-versus-host disease, and tolerance after different kinds of cell and whole organ transplantation from Lewis to brown Norway rats.

PubWeight™: 3.63‹?› | Rank: Top 1%

🔗 View Article (PMC 3003921)

Published in Transplantation on July 27, 1995


N Murase1, T E Starzl, M Tanabe, S Fujisaki, H Miyazawa, Q Ye, C P Delaney, J J Fung, A J Demetris

Author Affiliations

1: Transplantation Institute, University of Pittsburgh Medical Center, Pennsylvania, USA.

Articles citing this

Tolerogenic immunosuppression for organ transplantation. Lancet (2003) 4.09

Antigen localization and migration in immunity and tolerance. N Engl J Med (1998) 3.71

The lost chord: microchimerism and allograft survival. Immunol Today (1996) 2.81

Clinical intestinal transplantation: new perspectives and immunologic considerations. J Am Coll Surg (1998) 2.31

Transplantation tolerance from a historical perspective. Nat Rev Immunol (2001) 2.04

Microchimerism, dendritic cell progenitors and transplantation tolerance. Stem Cells (1995) 1.83

Apoptosis within spontaneously accepted mouse liver allografts: evidence for deletion of cytotoxic T cells and implications for tolerance induction. J Immunol (1997) 1.81

The saga of liver replacement, with particular reference to the reciprocal influence of liver and kidney transplantation (1955-1967). J Am Coll Surg (2002) 1.81

Transplantation tolerance, microchimerism, and the two-way paradigm. Theor Med Bioeth (1998) 1.67

Multilineage hematopoietic reconstitution of supralethally irradiated rats by syngeneic whole organ transplantation. With oarticular reference to the liver. Transplantation (1996) 1.65

Weaning of immunosuppression in liver transplant recipients. Transplantation (1997) 1.57

Immunomodulation for intestinal transplantation by allograft irradiation, adjunct donor bone marrow infusion, or both. Transplantation (2000) 1.53

Granulocyte/macrophage colony-stimulating factor-stimulated hepatic dendritic cell progenitors prolong pancreatic islet allograft survival. Transplantation (1995) 1.51

Clinical intestinal transplantation: a decade of experience at a single center. Ann Surg (2001) 1.44

Analysis of chronic rejection and obliterative arteriopathy. Possible contributions of donor antigen-presenting cells and lymphatic disruption. Am J Pathol (1997) 1.41

The current status of small bowel transplantation in the UK and internationally. Gut (2005) 1.31

Improved surgical technique for the establishment of a murine model of aortic transplantation. Microsurgery (1998) 1.10

Graft-versus-host disease after liver and small bowel transplantation in a child. Clin Transplant (1997) 1.09

Donor and recipient leukocytes in organ allografts of recipients with variable donor-specific tolerance: with particular reference to chronic rejection. Liver Transpl (2000) 1.07

Donor hematopoietic progenitor cells in nonmyeloablated rat recipients of allogeneic bone marrow and liver grafts. Transplantation (1999) 1.04

Acquired immunologic tolerance: with particular reference to transplantation. Immunol Res (2007) 0.97

Lessons of organ-induced tolerance learned from historical clinical experience. Transplantation (2004) 0.94

The unfinished legacy of liver transplantation: emphasis on immunology. Hepatology (2006) 0.93

Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection. J Clin Invest (1998) 0.93

Evolution of clinical intestinal transplantation: improved outcome and cost effectiveness. Transplant Proc (1999) 0.92

Increased apoptosis of immunoreactive host cells and augmented donor leukocyte chimerism, not sustained inhibition of B7 molecule expression are associated with prolonged cardiac allograft survival in mice preconditioned with immature donor dendritic cells plus anti-CD40L mAb. Transplantation (1999) 0.92

History of clinical transplantation. World J Surg (2000) 0.91

Augmentation of natural chimerism with donor bone marrow in orthotopic liver recipients. Transplant Proc (1996) 0.90

Four-color flow cytometric analysis of peripheral blood donor cell chimerism. Hum Immunol (2003) 0.89

Liver transplants contribute to their own success. Nat Med (1996) 0.89

Immunosuppressive therapy and tolerance of organ allografts. N Engl J Med (2008) 0.88

Abrogation of chronic rejection in a murine model of aortic allotransplantation by prior induction of donor-specific tolerance. Transplantation (1997) 0.87

Immunomodulation of intestinal transplant with allograft irradiation and simultaneous donor bone marrow infusion. Transplant Proc (1999) 0.86

Striking augmentation of hematopoietic cell chimerism in noncytoablated allogeneic bone marrow recipients by FLT3 ligand and tacrolimus. Transplantation (1997) 0.84

Effect in supralethally irradiated rats of granulocyte colony-stimulating factor and lisofylline on hematopoietic reconstitution by syngeneic bone marrow or whole organ passenger leukocytes. Transplantation (1997) 0.83

The loss of renal dendritic cells and activation of host adaptive immunity are long-term effects of ischemia/reperfusion injury following syngeneic kidney transplantation. Kidney Int (2012) 0.83

Simultaneous bone marrow and intestine transplantation promotes marrow-derived hematopoietic stem cell engraftment and chimerism. Blood (2006) 0.82

Early passenger leukocyte migration and acute immune reactions in the rat recipient spleen during liver engraftment: with particular emphasis on donor major histocompatibility complex class II+ cells. Transplantation (2002) 0.81

Donor pretreatment with Flt-3 ligand augments antidonor cytotoxic T lymphocyte, natural killer, and lymphokine-activated killer cell activities within liver allografts and alters the pattern of intragraft apoptotic activity. Transplantation (1998) 0.81

Tolerance and chimerism and allogeneic bone marrow/stem cell transplantation in liver transplantation. World J Gastroenterol (2013) 0.79

Chronic rejection. A general overview of histopathology and pathophysiology with emphasis on liver, heart and intestinal allografts. Ann Transplant (1997) 0.79

Evidence for the presence of multilineage chimerism and progenitors of donor dendritic cells in the peripheral blood of bone marrow-augmented organ transplant recipients. Transplantation (1997) 0.79

Relative contribution of direct and indirect allorecognition in developing tolerance after liver transplantation. Liver Transpl (2008) 0.78

The difficulty of eliminating donor leukocyte microchimerism in rat recipients bearing established organ allografts. Transplantation (2006) 0.78

Enhancement of donor cell chimerism in whole organ allograft recipients by adjuvant bone marrow transplantation. Transplant Proc (1995) 0.78

Allogeneic hematolymphoid microchimerism and prevention of autoimmune disease in the rat. A relationship between allo- and autoimmunity. J Clin Invest (1996) 0.77

Immunity and tolerance are related, and governed by antigen migration and localization. Transplant Proc (1999) 0.77

Clinical intestinal transplantation in 1998: Pittsburgh experience. Acta Gastroenterol Belg (1999) 0.77

The art of tolerance. Nat Med (1998) 0.76

Chimerism after organ transplantation. Curr Opin Nephrol Hypertens (1997) 0.76

The birth of clinical organ transplantation. J Am Coll Surg (2001) 0.76

The current status of hepatic transplantation at the University of Pittsburgh. Clin Transpl (1995) 0.76

Migration of donor MHC class II(+) cells and increase in apoptosis: correlate to graft outcome after heart and liver transplantation. Transplant Proc (2001) 0.75

[Allograft "acceptance" and tolerance: a new concept]. Bull Acad Natl Med (1998) 0.75

Prevention of Transplant Rejection: Can Tolerance be Achieved with Immunosuppressive Treatment? Clin Immunother (1996) 0.75

Clinical and basic scientific implications of cell migration and microchimerism after organ transplantation. Artif Organs (1997) 0.75

Chimerism, graft-vs-host disease, rejection, and their association with reciprocal donor-host immune reactions after cell, organ, and composite tissue transplantation. Transplant Proc (1997) 0.75

The role of cell migration and microchimerism in the induction of tolerance after solid organ transplantation. Postgrad Med J (1997) 0.75

Adult heart transplantation under tacrolimus (FK506) immunosuppression: histopathologic observations and comparison to a cyclosporine-based regimen with lympholytic (ATG) induction. J Heart Lung Transplant (1997) 0.75

Chimerism and xenotransplantation. New concepts. Surg Clin North Am (1999) 0.75

The immunolymphatic theory of chronic rejection. Transplant Proc (1997) 0.75

The changing immunology of organ transplantation. Hosp Pract (1995) (1995) 0.75

Effects of peritransplant administration of hematopoietic growth factors on the development of chronic allograft rejection. Transplant Proc (1999) 0.75

The bidirectional paradigm of transplant immunology. Ann N Y Acad Sci (1995) 0.75

Kinetics of Alloantigen-Specific Regulatory CD4 T Cell Development and Tissue Distribution After Donor-Specific Transfusion and Costimulatory Blockade. Transplant Direct (2016) 0.75

Tacrolimus (FK 506)-dependent tolerance after liver and heart xenotransplantation: inhibition of humoral response and acceptance of donor organs. Transplant Proc (1996) 0.75

Current perspectives of transplantation immunology via the intestine. Transplant Proc (1996) 0.75

Articles cited by this

(truncated to the top 100)

Actively acquired tolerance of foreign cells. Nature (1953) 19.82


Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Improved technique of heart transplantation in rats. J Thorac Cardiovasc Surg (1969) 8.26


Graft versus host reactions. Their natural history, and applicability as tools of research. Prog Allergy (1962) 7.11


Primarily vascularized allografts of hearts in mice. The role of H-2D, H-2K, and non-H-2 antigens in rejection. Transplantation (1973) 6.01

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Induction of immunological tolerance by porcine liver allografts. Nature (1969) 5.89

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Cytokines: coordinators of immune and inflammatory responses. Annu Rev Biochem (1990) 5.36

Prolonged survival of human-kidney homografts by immunosuppressive drug therapy. N Engl J Med (1963) 5.14

Orthotopic liver transplantation in the rat. Technique using cuff for portal vein anastomosis and biliary drainage. Transplantation (1979) 5.12

Transplantation of small bowel in the rat: technical and immunological considerations. Surgery (1971) 5.05

The impact on the developing embryo and newborn animal of adult homologous cells. Acta Pathol Microbiol Scand (1957) 5.02

A simple method for inducing tolerance of skin homografts in mice. Transplant Bull (1957) 4.73

Immunological reconstitution of sex-linked lymphopenic immunological deficiency. Lancet (1968) 4.41

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Reconstitution with syngeneic plus allogeneic or xenogeneic bone marrow leads to specific acceptance of allografts or xenografts. Nature (1984) 4.26

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Induction of specific tissue transplantation tolerance using fractionated total lymphoid irradiation in adult mice: long-term survival of allogeneic bone marrow and skin grafts. J Exp Med (1977) 3.48

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Human renal transplantation. I. Clinical experiences with six cases of renal homotransplantation. J Urol (1963) 3.35

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Chimerism and donor-specific nonreactivity 27 to 29 years after kidney allotransplantation. Transplantation (1993) 3.13

Long-term engraftment of normal and post-5-fluorouracil murine marrow into normal nonmyeloablated mice. Blood (1993) 3.08

Reversal of transplantation immunity by liver grafting. Nature (1981) 3.07

Renal homotransplantation in man after radiation of the recipient. Experience with six patients since 1959. Am J Med (1962) 3.04

Hematolymphoid cell trafficking, microchimerism, and GVH reactions after liver, bone marrow, and heart transplantation. Transplant Proc (1993) 2.81

Propagation of dendritic cell progenitors from normal mouse liver using granulocyte/macrophage colony-stimulating factor and their maturational development in the presence of type-1 collagen. J Exp Med (1994) 2.48

Soluble HLA antigens in the circulation of liver graft recipients. Transplantation (1989) 2.48

Long-term results of a controlled prospective study with transfusion of donor-specific bone marrow in 57 cadaveric renal allograft recipients. Transplantation (1991) 2.32

On the acquisition of tolerance by adult cells. Ann N Y Acad Sci (1960) 2.32

Bone-marrow transplantation in a patient with the Wiskott-Aldrich syndrome. Lancet (1968) 2.29

Hemopoietic cell growth factors and their receptors. Annu Rev Biochem (1989) 2.28

Transplantation milestones. Viewed with one- and two-way paradigms of tolerance. JAMA (1995) 2.20

Some recent advances in cardiac pathology. Hum Pathol (1979) 2.17

Successful skin homografts after the administration of high dosage X radiation and homologous bone marrow. J Natl Cancer Inst (1955) 2.16

Graft-versus-host disease after brown Norway-to-Lewis and Lewis-to-Brown Norway rat intestinal transplantation under FK506. Transplantation (1993) 2.14

Prolonged survival of liver transplants in the pig. Br Med J (1967) 2.14

Study on transplantation immunity after total body irradiation: clinical and experimental investigation. Surgery (1960) 2.07

Kidney transplants in mice. An analysis of the immune status of mice bearing long-term, H-2 incompatible transplants. J Exp Med (1978) 1.95

Lymphocyte traffic and graft-versus-host disease after fully allogeneic small bowel transplantation. Transplant Proc (1991) 1.89

Growth of donor-derived dendritic cells from the bone marrow of murine liver allograft recipients in response to granulocyte/macrophage colony-stimulating factor. J Exp Med (1995) 1.88

Possible active enhancement of a human cadaver renal allograft with antilymphocyte serum (ALS) and donor bone marrow: case report of an initial attempt. Surgery (1976) 1.84


Homologous human kidney transplantation. Experience with six patients. Postgrad Med J (1962) 1.80

Early events in liver allograft rejection. Delineation of sites of simultaneous intragraft and recipient lymphoid tissue sensitization. Am J Pathol (1991) 1.78

The major histocompatibility complex of the rat. Transplantation (1987) 1.76

Quantitative studies on the ability of cells of different origins to induce tolerance of skin homografts and cause runt disease in neonatal mice. J Exp Zool (1961) 1.76

Fully allogeneic liver grafting in rats induces a state of systemic nonreactivity to donor transplantation antigens. Transplantation (1980) 1.71

Augmenter of liver regeneration: its place in the universe of hepatic growth factors. Hepatology (1994) 1.70

Induction of tolerance of skin homografts in immunologically competent mice. Nature (1962) 1.69

Observations of orthotopic liver transplantation in the pig. Br Med J (1967) 1.69

The homotransplantation of kidneys and of fetal liver and spleen after total body irradiation. Ann Surg (1960) 1.68

Inhibition of the rejection of renal homografts in dogs by purine analogues. Transplant Bull (1961) 1.64

Donor dendritic cells after liver and heart allotransplantation under short-term immunosuppression. Lancet (1992) 1.61

Split tolerance induced by orthotopic liver transplantation in mice. Transplantation (1994) 1.52

Hematopoietic growth factors. Biology and clinical applications. N Engl J Med (1989) 1.48

A functioning kidney homotransplant in the dog. Surgery (1959) 1.45

Transplantation tolerance in adult rats using total lymphoid irradiation: permanent survival of skin, heart, and marrow allografts. J Exp Med (1978) 1.44

An immunological suppressor cell inactivating cytotoxic T-lymphocyte precursor cells recognizing it. Nature (1980) 1.40

Microchimerism: a stable state of low-ratio proliferation of allogeneic bone marrow. Transplant Proc (1977) 1.39

Class I transplantation antigens in solution in body fluids and in the urine. Individuality signals to the environment. J Exp Med (1988) 1.39

Effect of selective T cell depletion of host and/or donor bone marrow on lymphopoietic repopulation, tolerance, and graft-vs-host disease in mixed allogeneic chimeras (B10 + B10.D2----B10). J Immunol (1986) 1.39

Post transplantation donor-specific bone marrow transfusion in polyclonal antilymphocyte serum-treated recipients: the optimal cellular antigen for induction of unresponsiveness to organ allografts. Transplant Proc (1988) 1.38

Further studies of veto activity in rhesus monkey bone marrow in relation to allograft tolerance and chimerism. Transplantation (1994) 1.37

[Orthotopic liver graft in pigs. 1st results]. Mem Acad Chir (Paris) (1966) 1.35

Cells in bone marrow and in T cell colonies grown from bone marrow can suppress generation of cytotoxic T lymphocytes directed against their self antigens. J Exp Med (1980) 1.35

An investigation of immunological tolerance based on chimaera analysis. Immunology (1961) 1.34

Mixed allogeneic chimerism as an approach to transplantation tolerance. Immunol Today (1988) 1.33

Essential duration of parabiosis and development of tolerance to skin homografts in mice. Proc Soc Exp Biol Med (1960) 1.31

Canine liver homotransplants. The effect of host and graft irradiation. Arch Surg (1962) 1.23

Studies on heterologous antilymphocyte serum in mice. VII. Optimal cellular antigen for induction of immunologic tolerance with antilymphocyte serum. Transplant Proc (1970) 1.22

Competitive repopulation in unirradiated normal recipients. Blood (1993) 1.20

Promotion of incompatible allograft acceptance in rhesus monkeys given posttransplant antithymocyte globulin and donor bone marrow. I. In vivo parameters and immunohistologic evidence suggesting microchimerism. Transplantation (1987) 1.20

Enhanced survival of canine renal allografts of ALS- treated dogs given bone marrow. Transplant Proc (1973) 1.20

Renal allograft tolerance induced with ATG and donor bone marrow in outbred rhesus monkeys. Transplantation (1983) 1.19

Donor-specific bone marrow infusion after orthotopic liver transplantation. Lancet (1994) 1.18

Production of granulocyte-macrophage colony-stimulating factor by adult murine parenchymal liver cells (hepatocytes). Reg Immunol (1991) 1.17

Specific transplantation tolerance induced by spontaneously tolerated liver allograft in inbred strains of rats. Transplantation (1980) 1.16

Use of homozygous allogeneic bone marrow for induction of tolerance with antilymphocyte serum: dose and timing. Transplant Proc (1971) 1.16

Peripheral blood chimerism in renal allograft recipients transfused with donor bone marrow. Transplantation (1994) 1.16

Donor-derived chimerism in recipients of organ transplants. Hepatology (1993) 1.15

Organ graft tolerance: the liver effect. Lancet (1994) 1.14

In vitro propagation and homing of liver-derived dendritic cell progenitors to lymphoid tissues of allogeneic recipients. Implications for the establishment and maintenance of donor cell chimerism following liver transplantation. Transplantation (1995) 1.06

The influence of donor and recipient strains in isolated small bowel transplantation in rats. Transplant Proc (1994) 1.04

In vivo and in vitro characterization of specific hyporeactivity to skin xenografts in mixed xenogeneically reconstituted mice (B10 + F344 rat----B10). J Exp Med (1984) 1.04

The liver as a potential hematolymphoid organ examined from modifications occurring in the systemic and intrahepatic hematolymphoid system during liver regeneration after partial hepatectomy. Reg Immunol (1992) 1.03

Specific suppression of allograft rejection by soluble class I antigen and complexes with monoclonal antibody. Transplantation (1990) 1.01

Specific unresponsiveness to skin allografts in anti-lymphocyte serum-treated, marrow-injected mice: participation of donor marrow-derived suppressor T cells. J Immunol (1981) 1.00

Use of cryopreserved donor bone marrow in cadaver kidney allograft recipients. Transplantation (1989) 1.00

Orthotopic liver allografts in the rat. The influence of strain combination on the fate of the graft. Transplantation (1984) 1.00

Immunosuppressive effects of the morpholinoethyl ester of mycophenolic acid (RS-61443) in rat and nonhuman primate recipients of heart allografts. Transplant Proc (1991) 0.98

Tolerance reconsidered--a critical survey. Transplant Proc (1973) 0.98

Immunological tolerance and enhancement: a common mechanism. Transplant Proc (1971) 0.97

In vivo administration of histoincompatible lymphocytes leads to rapid functional deletion of cytotoxic T lymphocyte precursors. J Exp Med (1989) 0.93

Articles by these authors

Evolution of liver transplantation. Hepatology (1982) 19.54

FK 506 for liver, kidney, and pancreas transplantation. Lancet (1989) 13.70

Cell migration, chimerism, and graft acceptance. Lancet (1992) 12.24

A flexible procedure for multiple cadaveric organ procurement. Surg Gynecol Obstet (1984) 10.33

The Banff 97 working classification of renal allograft pathology. Kidney Int (1999) 9.02

Cell migration and chimerism after whole-organ transplantation: the basis of graft acceptance. Hepatology (1993) 8.76

Orthotopic liver transplantation in ninety-three patients. Surg Gynecol Obstet (1976) 8.11

Sites of alcohol and volatile anaesthetic action on GABA(A) and glycine receptors. Nature (1997) 7.49

The use of cyclosporin A and prednisone in cadaver kidney transplantation. Surg Gynecol Obstet (1980) 7.40

The use of heterologous antilymphoid agents in canine renal and liver homotransplantation and in human renal homotransplantation. Surg Gynecol Obstet (1967) 7.24

Fifteen years of clinical liver transplantation. Gastroenterology (1979) 7.19

Venous bypass in clinical liver transplantation. Ann Surg (1984) 7.04

Liver transplantation with use of cyclosporin a and prednisone. N Engl J Med (1981) 6.95

The many faces of multivisceral transplantation. Surg Gynecol Obstet (1991) 6.89

Orthotopic homotransplantation of the human liver. Ann Surg (1968) 6.64

Vascular homografts from cadaveric organ donors. Surg Gynecol Obstet (1979) 6.23

Long survival in rats after multivisceral versus isolated small-bowel allotransplantation under FK 506. Surgery (1991) 5.92

Infections after liver transplantation. An analysis of 101 consecutive cases. Medicine (Baltimore) (1988) 5.77

Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet (1984) 5.74

Refinements in the surgical technique of liver transplantation. Semin Liver Dis (1985) 5.70

Bone marrow augmentation of donor-cell chimerism in kidney, liver, heart, and pancreas islet transplantation. Lancet (1994) 5.54

Progress in and deterrents to orthotopic liver transplantation, with special reference to survival, resistance to hyperacute rejection, and biliary duct reconstruction. Transplant Proc (1974) 5.53

Extended survival in 3 cases of orthotopic homotransplantation of the human liver. Surgery (1968) 5.44

Banff '05 Meeting Report: differential diagnosis of chronic allograft injury and elimination of chronic allograft nephropathy ('CAN'). Am J Transplant (2007) 5.39

Cyclophosphamide and whole organ transplantation in human beings. Surg Gynecol Obstet (1971) 5.24

Alternative methods of arterialization of the hepatic graft. Surg Gynecol Obstet (1984) 5.16

Immunosuppression of canine, monkey, and baboon allografts by FK 506: with special reference to synergism with other drugs and to tolerance induction. Surgery (1988) 5.03

Liver, kidney, and thoracic organ transplantation under FK 506. Ann Surg (1990) 5.01

Intestinal transplantation in composite visceral grafts or alone. Ann Surg (1992) 4.96

Conversion from cyclosporine to FK 506 in liver allograft recipients with cyclosporine-related complications. Transplant Proc (1990) 4.90

Liver transplantation (1). N Engl J Med (1989) 4.53

Pancreaticoduodenal transplantation in humans. Surg Gynecol Obstet (1984) 4.49

Genetic analysis of novel avian A(H7N9) influenza viruses isolated from patients in China, February to April 2013. Euro Surveill (2013) 4.44

Culture conditions for stimulating cholera toxin production by Vibrio cholerae O1 El Tor. Microbiol Immunol (1986) 4.38

Murine liver allograft transplantation: tolerance and donor cell chimerism. Hepatology (1994) 4.32

A simplified technique for revascularization of homografts of the liver with a variant right hepatic artery from the superior mesenteric artery. Surg Gynecol Obstet (1985) 4.29

Donor cell chimerism permitted by immunosuppressive drugs: a new view of organ transplantation. Immunol Today (1993) 4.29

Heterotopic heart transplantation in the rat receiving FK-506 alone or with cyclosporine. Transplant Proc (1987) 4.21

Pancreatic islet transplantation after upper abdominal exenteration and liver replacement. Lancet (1990) 4.18

Experience in hepatic resection for metastatic colorectal cancer: analysis of clinical and pathologic risk factors. Surgery (1994) 4.16

Orthotopic liver transplantation with preservation of the inferior vena cava. Ann Surg (1989) 4.12

Malignant lymphomas in transplantation patients. Transplant Proc (1969) 4.12

Role of liver transplantation in cancer therapy. Ann Surg (1985) 4.08

Biliary complications after liver transplantation: with special reference to the biliary cast syndrome and techniques of secondary duct repair. Surgery (1977) 4.08

Shwartzman reaction after human renal homotransplantation. N Engl J Med (1968) 4.05

Baboon-to-human liver transplantation. Lancet (1993) 4.01

Extended preservation of human liver grafts with UW solution. JAMA (1989) 3.99

Canine and human liver preservation for 6 to 18 hr by cold infusion. Transplantation (1977) 3.99

Liver transplantation in the United States, 1999-2008. Am J Transplant (2010) 3.92

Clinical presentation of hepatic artery thrombosis after liver transplantation in the cyclosporine era. Transplantation (1985) 3.91

The preparation and testing of horse antidog and antihuman antilymphoid plasma or serum and its protein fractions. Surg Gynecol Obstet (1967) 3.86

Replacement of donor lymphoid tissue in small-bowel transplants. Lancet (1991) 3.85

The origin, hormonal nature, and action of hepatotrophic substances in portal venous blood. Surg Gynecol Obstet (1973) 3.84

Effects of insulin, glucagon, and insuling/glucagon infusions on liver morphology and cell division after complete portacaval shunt in dogs. Lancet (1976) 3.74

Immunosuppressive effect of FK-506 on in vitro lymphocyte alloactivation: synergism with cyclosporine A. Transplant Proc (1987) 3.73

Spatiotemporal dynamics of inositol 1,4,5-trisphosphate that underlies complex Ca2+ mobilization patterns. Science (1999) 3.70

Hepatic trisegmentectomy and other liver resections. Surg Gynecol Obstet (1975) 3.66

Right trisegmentectomy for hepatic neoplasms. Surg Gynecol Obstet (1980) 3.64

Systemic chimerism in human female recipients of male livers. Lancet (1992) 3.63

Hepatic Retransplantation. Transplant Proc (1985) 3.62

Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg (1991) 3.57

Canine kidney transplantation with FK-506 alone or in combination with cyclosporine and steroids. Transplant Proc (1987) 3.55

Canine liver transplantation under Nva2-cyclosporine versus cyclosporine. Transplantation (1986) 3.54

Combination donor hepatectomy and nephrectomy and early functional results of allografts. Surg Gynecol Obstet (1982) 3.49

Long-term survival after renal transplantation in humans: (with special reference to histocompatibility matching, thymectomy, homograft glomerulonephritis, heterologous ALG , AND RECIPIENT MALIGNANCY). Ann Surg (1970) 3.48

Banff 2013 meeting report: inclusion of c4d-negative antibody-mediated rejection and antibody-associated arterial lesions. Am J Transplant (2014) 3.43

Selected topics on FK 506, with special references to rescue of extrahepatic whole organ grafts, transplantation of "forbidden organs," side effects, mechanisms, and practical pharmacokinetics. Transplant Proc (1991) 3.40

Nephrotoxicity of cyclosporin A in liver and kidney transplant patients. Lancet (1981) 3.38

The relation of preoperative coagulation findings to diagnosis, blood usage, and survival in adult liver transplantation. Transplantation (1985) 3.38

Chimerism after liver transplantation for type IV glycogen storage disease and type 1 Gaucher's disease. N Engl J Med (1993) 3.36

Orthotopic liver transplantation for patients with hepatitis B virus-related liver disease. Hepatology (1991) 3.34

Kidney transplantation under FK 506 immunosuppression. Transplant Proc (1991) 3.31

Early trials with FK 506 as primary treatment in liver transplantation. Transplant Proc (1990) 3.29

Banff '09 meeting report: antibody mediated graft deterioration and implementation of Banff working groups. Am J Transplant (2010) 3.29

Use of OKT3 with cyclosporin and steroids for reversal of acute kidney and liver allograft rejection. Nephron (1987) 3.26

Delayed biliary duct obstruction after orthotopic liver transplantation. Surgery (1972) 3.26

The pathology of posttransplant lymphoproliferative disorders occurring in the setting of cyclosporine A-prednisone immunosuppression. Am J Pathol (1988) 3.24

Changes in blood coagulation. Arch Surg (1966) 3.22

Rejection of multivisceral allografts in rats: a sequential analysis with comparison to isolated orthotopic small-bowel and liver grafts. Surgery (1990) 3.18

Renal transplantation in baboons under FK 506. Surgery (1989) 3.17

Intraoperative changes in blood coagulation and thrombelastographic monitoring in liver transplantation. Anesth Analg (1985) 3.17

Pathology of hepatic transplantation: A review of 62 adult allograft recipients immunosuppressed with a cyclosporine/steroid regimen. Am J Pathol (1985) 3.16